Skip to main content

Kelly John Alexander's Form 4 filing

Precision Biosciences Inc (DTIL) · filed Jan 22, 2026

Accession no.
0001628280-26-003147
Filed
Jan 22, 2026
Trade date
Jan 20-21, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $61.3K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kelly John AlexanderCIK 0001590030Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 20, 2026Common StockMOption exerciseAcquired+3,888––81,186Direct
Jan 20, 2026Common StockMOption exerciseAcquired+13,900––95,086Direct
Jan 20, 2026Common StockMOption exerciseAcquired+26,575––121,661Direct
Jan 21, 2026Common StockSSaleDisposed−15,213$4.03−$61,308.39106,448Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 20, 2026Common StockMOption exerciseDisposed−3,888$0.00$00Direct
Jan 20, 2026Common StockMOption exerciseDisposed−13,900$0.00$013,901Direct
Jan 20, 2026Common StockMOption exerciseDisposed−26,575$0.00$026,575Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)